olfactory receptor family 11 subfamily Q member 1 pseudogeneGenealiases: []
Q-omics provides the consensus-scored OR11Q1P profile across patient tissues and cancer cell-line models. OR11Q1P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, OR11Q1P is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, OR11Q1P RNA expression shows 6,135 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, BRCA, and STAD as cancer lineages where OR11Q1P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for OR11Q1P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes OR11Q1P survival associations across molecular data types. OR11Q1P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible OR11Q1P RNA expression–survival associations across cancer types. High OR11Q1P expression shows unfavorable associations in KIRC, STAD, READ, LUSC and LUAD, but favorable associations in BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for OR11Q1P RNA expression.
This table summarizes OR11Q1P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for OR11Q1P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. OR11Q1P shows lower tumor expression in BRCA and higher tumor expression in LIHC, THCA, CHOL and LUSC. The BRCA box plot shows higher OR11Q1P RNA expression in normal versus tumor tissue (log2 FC = −0.366, t-test p < 0.001).
This table shows molecular features associated with OR11Q1P in patient tissues and cancer cell lines. In patient samples, OR11Q1P shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
